asn51
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 2, 2021 (NCT04759365)
Timeline
Indications
Mechanism of action
- Bifunctional protein NCOATINHIBITOR
OGA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06677203 | Phase 2 | Oct 16, 2024 | Asceneuron S.A. |
| NCT06232109 | Phase 1 | Feb 22, 2024 | Asceneuron S.A., QPS |
| NCT05725005 | Phase 1 | Feb 6, 2023 | Asceneuron S.A., Hammersmith Medicines Research, Invicro |
| NCT06390098 | Phase 1 | Aug 9, 2021 | Asceneuron S.A. |
| NCT04759365 | Phase 1 | Jun 2, 2021 | Asceneuron Pty Ltd., Asceneuron S.A., Neuroscience Trials Australia |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asceneuron S.A. | For profit | 5 | 4 | 2 | 2021 |
| Asceneuron Pty Ltd. | For profit | 1 | 1 | 1 | 2021 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2023 |
| Invicro | For profit | 1 | 0 | 1 | 2023 |
| Neuroscience Trials Australia | Academic/Hospital | 1 | 0 | 1 | 2021 |
| QPS | For profit | 1 | 0 | 1 | 2024 |
6 organizations
Page 1 / 1